Matches in SemOpenAlex for { <https://semopenalex.org/work/W2604832074> ?p ?o ?g. }
- W2604832074 endingPage "87.e1" @default.
- W2604832074 startingPage "79" @default.
- W2604832074 abstract "BackgroundTofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated.ObjectiveWe sought to assess the efficacy of tofacitinib for the treatment of nail psoriasis over a period of 52 weeks.MethodsIn 2 identical phase 3 studies (OPT Pivotal 1 and 2), patients were randomized 2:2:1 to receive tofacitinib 5 mg, tofacitinib 10 mg, or placebo, twice daily. At week 16, placebo-treated patients were re-randomized to tofacitinib. This post hoc analysis of patients with existing nail psoriasis assessed the Nail Psoriasis Severity Index (NAPSI) score and proportions of patients achieving ≥50% reduction in NAPSI from baseline (NAPSI50), NAPSI75, or NAPSI100.ResultsBaseline mean NAPSI scores for patients treated with tofacitinib 5 mg (N = 487), tofacitinib 10 mg (N = 476), and placebo (N = 233) twice daily were 27.0, 27.3, and 26.9, respectively. At week 16, significantly (all P < .05) more patients receiving tofacitinib 5 mg and tofacitinib 10 mg versus placebo twice daily achieved NAPSI50 (32.8%, 44.2% vs 12.0%), NAPSI75 (16.9%, 28.1% vs 6.8%), and NAPSI100 (10.3%, 18.2% vs 5.1%), respectively. Improvements were sustained to week 52.LimitationsLimitations include discontinuation of clinical nonresponders at week 28.ConclusionsTofacitinib treatment resulted in improvements in nail psoriasis versus placebo at week 16; improvements were maintained over 52 weeks [NCT01276639; NCT01309737]. Tofacitinib is an oral Janus kinase inhibitor. Efficacy and safety of tofacitinib in patients with moderate-to-severe plaque psoriasis have been demonstrated. We sought to assess the efficacy of tofacitinib for the treatment of nail psoriasis over a period of 52 weeks. In 2 identical phase 3 studies (OPT Pivotal 1 and 2), patients were randomized 2:2:1 to receive tofacitinib 5 mg, tofacitinib 10 mg, or placebo, twice daily. At week 16, placebo-treated patients were re-randomized to tofacitinib. This post hoc analysis of patients with existing nail psoriasis assessed the Nail Psoriasis Severity Index (NAPSI) score and proportions of patients achieving ≥50% reduction in NAPSI from baseline (NAPSI50), NAPSI75, or NAPSI100. Baseline mean NAPSI scores for patients treated with tofacitinib 5 mg (N = 487), tofacitinib 10 mg (N = 476), and placebo (N = 233) twice daily were 27.0, 27.3, and 26.9, respectively. At week 16, significantly (all P < .05) more patients receiving tofacitinib 5 mg and tofacitinib 10 mg versus placebo twice daily achieved NAPSI50 (32.8%, 44.2% vs 12.0%), NAPSI75 (16.9%, 28.1% vs 6.8%), and NAPSI100 (10.3%, 18.2% vs 5.1%), respectively. Improvements were sustained to week 52. Limitations include discontinuation of clinical nonresponders at week 28. Tofacitinib treatment resulted in improvements in nail psoriasis versus placebo at week 16; improvements were maintained over 52 weeks [NCT01276639; NCT01309737]." @default.
- W2604832074 created "2017-04-14" @default.
- W2604832074 creator A5012671195 @default.
- W2604832074 creator A5025545596 @default.
- W2604832074 creator A5030104352 @default.
- W2604832074 creator A5067129386 @default.
- W2604832074 creator A5075354896 @default.
- W2604832074 creator A5076696600 @default.
- W2604832074 date "2017-07-01" @default.
- W2604832074 modified "2023-10-16" @default.
- W2604832074 title "Efficacy of tofacitinib for the treatment of nail psoriasis: Two 52-week, randomized, controlled phase 3 studies in patients with moderate-to-severe plaque psoriasis" @default.
- W2604832074 cites W1882277951 @default.
- W2604832074 cites W1892175722 @default.
- W2604832074 cites W1986989304 @default.
- W2604832074 cites W1990570855 @default.
- W2604832074 cites W2024708086 @default.
- W2604832074 cites W2028648418 @default.
- W2604832074 cites W2035059473 @default.
- W2604832074 cites W2039852889 @default.
- W2604832074 cites W2043183494 @default.
- W2604832074 cites W2062894469 @default.
- W2604832074 cites W2088082438 @default.
- W2604832074 cites W2097935815 @default.
- W2604832074 cites W2115555204 @default.
- W2604832074 cites W2116232969 @default.
- W2604832074 cites W2120422600 @default.
- W2604832074 cites W2138647255 @default.
- W2604832074 cites W2140061052 @default.
- W2604832074 cites W2157964761 @default.
- W2604832074 cites W2168607358 @default.
- W2604832074 cites W2283622962 @default.
- W2604832074 cites W2313199171 @default.
- W2604832074 cites W4253184167 @default.
- W2604832074 cites W920413449 @default.
- W2604832074 doi "https://doi.org/10.1016/j.jaad.2017.01.053" @default.
- W2604832074 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28396102" @default.
- W2604832074 hasPublicationYear "2017" @default.
- W2604832074 type Work @default.
- W2604832074 sameAs 2604832074 @default.
- W2604832074 citedByCount "63" @default.
- W2604832074 countsByYear W26048320742017 @default.
- W2604832074 countsByYear W26048320742018 @default.
- W2604832074 countsByYear W26048320742019 @default.
- W2604832074 countsByYear W26048320742020 @default.
- W2604832074 countsByYear W26048320742021 @default.
- W2604832074 countsByYear W26048320742022 @default.
- W2604832074 countsByYear W26048320742023 @default.
- W2604832074 crossrefType "journal-article" @default.
- W2604832074 hasAuthorship W2604832074A5012671195 @default.
- W2604832074 hasAuthorship W2604832074A5025545596 @default.
- W2604832074 hasAuthorship W2604832074A5030104352 @default.
- W2604832074 hasAuthorship W2604832074A5067129386 @default.
- W2604832074 hasAuthorship W2604832074A5075354896 @default.
- W2604832074 hasAuthorship W2604832074A5076696600 @default.
- W2604832074 hasBestOaLocation W26048320741 @default.
- W2604832074 hasConcept C126322002 @default.
- W2604832074 hasConcept C141071460 @default.
- W2604832074 hasConcept C142724271 @default.
- W2604832074 hasConcept C16005928 @default.
- W2604832074 hasConcept C168563851 @default.
- W2604832074 hasConcept C204787440 @default.
- W2604832074 hasConcept C27081682 @default.
- W2604832074 hasConcept C2776233030 @default.
- W2604832074 hasConcept C2777011040 @default.
- W2604832074 hasConcept C2777575956 @default.
- W2604832074 hasConcept C2778715236 @default.
- W2604832074 hasConcept C2778886723 @default.
- W2604832074 hasConcept C2780158451 @default.
- W2604832074 hasConcept C2780564577 @default.
- W2604832074 hasConcept C71924100 @default.
- W2604832074 hasConcept C90924648 @default.
- W2604832074 hasConceptScore W2604832074C126322002 @default.
- W2604832074 hasConceptScore W2604832074C141071460 @default.
- W2604832074 hasConceptScore W2604832074C142724271 @default.
- W2604832074 hasConceptScore W2604832074C16005928 @default.
- W2604832074 hasConceptScore W2604832074C168563851 @default.
- W2604832074 hasConceptScore W2604832074C204787440 @default.
- W2604832074 hasConceptScore W2604832074C27081682 @default.
- W2604832074 hasConceptScore W2604832074C2776233030 @default.
- W2604832074 hasConceptScore W2604832074C2777011040 @default.
- W2604832074 hasConceptScore W2604832074C2777575956 @default.
- W2604832074 hasConceptScore W2604832074C2778715236 @default.
- W2604832074 hasConceptScore W2604832074C2778886723 @default.
- W2604832074 hasConceptScore W2604832074C2780158451 @default.
- W2604832074 hasConceptScore W2604832074C2780564577 @default.
- W2604832074 hasConceptScore W2604832074C71924100 @default.
- W2604832074 hasConceptScore W2604832074C90924648 @default.
- W2604832074 hasIssue "1" @default.
- W2604832074 hasLocation W26048320741 @default.
- W2604832074 hasLocation W26048320742 @default.
- W2604832074 hasOpenAccess W2604832074 @default.
- W2604832074 hasPrimaryLocation W26048320741 @default.
- W2604832074 hasRelatedWork W1545824045 @default.
- W2604832074 hasRelatedWork W2113082323 @default.
- W2604832074 hasRelatedWork W2248533790 @default.
- W2604832074 hasRelatedWork W2508182513 @default.
- W2604832074 hasRelatedWork W2752345645 @default.
- W2604832074 hasRelatedWork W2755978387 @default.